SPY756.89−0.38%QQQ685.87−0.65%BTC/USD73,833.41+0.18%DIA524.40−0.01%GLD365.23+0.02%TLT80.86−0.07%

Sabra Health Care REIT Inc

SBRANASDAQ

$20.97

-0.35-1.64%

Last update: Nov 11, 4:00 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Dividend: The dividend Ex-Date is tomorrow

Sabra Health Care REIT (SBRA) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Sabra Health Care REIT (SBRA) stock.

Analyst Consensus — 14 Analysts

3S.Buy

5Buy

5Hold

1Sell

# Analysts14

Latest Upgrades and Downgrades for Sabra Health Care REIT Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	UBS	Michael Goldsmith	PT Raise	Neutral	$20→$22
—	Wells Fargo	James Feldman	PT Cut	Overweight	$23→$21
—	UBS	Michael Goldsmith	PT Cut	Neutral	$21→$20
—	Barclays	Richard Hightower	PT Cut	Equal-Weight	$23→$21
—	Barclays	Richard Hightower	PT Raise	Equal-Weight	$21→$23
—	Baird	Vikram Malhotra	PT Raise	Neutral	$20→$21
—	Raymond James	David Rodgers	Upgrade	Underperform→Market Perform	—
—	Baird	Wesley Golladay	PT Raise	Neutral	$22→$23
—	Truist Securities	Michael Lewis	PT Raise	Buy	$22→$24
—	Citizens	Aaron Hecht	PT Raise	Market Outperform	$23→$25
—	UBS	Michael Goldsmith	PT Cut	Neutral	$22→$21
—	Truist Securities	Michael Lewis	Upgrade	Hold→Buy	$22
—	Barclays	Richard Hightower	Initiate	Equal-Weight	$21
—	Citigroup	Nick Joseph	Downgrade	Buy→Neutral	$24→$19
—	Scotiabank	Nicholas Yulico	PT Cut	Sector Perform	$22→$19
—	Raymond James	David Rodgers	Reinstates	Market Perform→Underperform	—
—	Wells Fargo	John Kilichowski	PT Raise	Overweight	$22→$23
—	Scotiabank	Nicholas Yulico	PT Raise	Sector Perform	$21→$22
—	UBS	Michael Goldsmith	PT Raise	Neutral	$21→$22
—	Cantor Fitzgerald	Richard Anderson	PT Raise	Neutral	$21→$22

Sabra Health Care REIT Inc

Sabra Health Care REIT (SBRA) Stock Price Target 2026

Latest Upgrades and Downgrades for Sabra Health Care REIT Stock

Sabra Health Care REIT (SBRA) Stock Price Target 2026

Latest Upgrades and Downgrades for Sabra Health Care REIT Stock

Analyst Ratings News

PRO
UBS Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $22

PRO
Wells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $21

PRO
UBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Lowers Price Target to $21

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23

PRO
Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21

People Also Watch

People Also Watch

Analyst Ratings News

PRO
UBS Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $22

PRO
Wells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $21

PRO
UBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Lowers Price Target to $21

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23

PRO
Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21

Sabra Health Care REIT Inc

Sabra Health Care REIT (SBRA) Stock Price Target 2026

Latest Upgrades and Downgrades for Sabra Health Care REIT Stock

Sabra Health Care REIT (SBRA) Stock Price Target 2026

Latest Upgrades and Downgrades for Sabra Health Care REIT Stock

Analyst Ratings News

PROUBS Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $22

PROWells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $21

PROUBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20

PROBarclays Maintains Equal-Weight on Sabra Health Care REIT, Lowers Price Target to $21

PROBarclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23

PROBaird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21

People Also Watch

People Also Watch

Analyst Ratings News

PROUBS Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $22

PROWells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $21

PROUBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20

PROBarclays Maintains Equal-Weight on Sabra Health Care REIT, Lowers Price Target to $21

PROBarclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23

PROBaird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21

PRO
UBS Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $22

PRO
Wells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $21

PRO
UBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Lowers Price Target to $21

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23

PRO
Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21

PRO
UBS Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $22

PRO
Wells Fargo Maintains Overweight on Sabra Health Care REIT, Lowers Price Target to $21

PRO
UBS Maintains Neutral on Sabra Health Care REIT, Lowers Price Target to $20

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Lowers Price Target to $21

PRO
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23

PRO
Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21